Mariner’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$72.9M Buy
384,328
+12,405
+3% +$2.33M 0.08% 203
2026
Q1
$73.3M Buy
371,923
+26,763
+8% +$5.16M 0.09% 188
2025
Q4
$63.5M Buy
345,160
+8,900
+3% +$1.56M 0.08% 213
2025
Q3
$51.6M Buy
336,260
+5,219
+2% +$790K 0.07% 241
2025
Q2
$46.3M Buy
331,041
+103,247
+45% +$14.5M 0.07% 254
2025
Q1
$33.5M Buy
227,794
+125,009
+122% +$18.1M 0.06% 278
2024
Q4
$13.5M Buy
102,785
+12,999
+14% +$1.82M 0.02% 460
2024
Q3
$14M Buy
89,786
+2,927
+3% +$472K 0.02% 438
2024
Q2
$13.5M Buy
86,859
+29,237
+51% +$4.4M 0.03% 423
2024
Q1
$7.81M Sell
57,622
-13,557
-19% -$1.8M 0.02% 579
2023
Q4
$9.59M Sell
71,179
-1,436
-2% -$187K 0.02% 483
2023
Q3
$9.83M Sell
72,615
-2,834
-4% -$387K 0.03% 439
2023
Q2
$10.8M Buy
75,449
+1,993
+3% +$293K 0.03% 416
2023
Q1
$10.2M Buy
73,456
+16,963
+30% +$2.28M 0.03% 431
2022
Q4
$7.66M Sell
56,493
-2,809
-5% -$352K 0.02% 473
2022
Q3
$6.5M Buy
59,302
+29,229
+97% +$3.71M 0.03% 439
2022
Q2
$3.97M Sell
30,073
-1,243
-4% -$163K 0.02% 543
2022
Q1
$4.16M Buy
31,316
+2,369
+8% +$284K 0.02% 538
2021
Q4
$3.37M Buy
28,947
+5,768
+25% +$679K 0.01% 518
2021
Q3
$2.78M Buy
23,179
+5,128
+28% +$597K 0.01% 464
2021
Q2
$2.16M Buy
18,051
+981
+6% +$108K 0.01% 473
2021
Q1
$1.7M Buy
17,070
+2,488
+17% +$250K 0.01% 489
2020
Q4
$1.46M Sell
14,582
-3,706
-20% -$393K 0.01% 491
2020
Q3
$2M Sell
18,288
-1,279
-7% -$142K 0.02% 373
2020
Q2
$2.07M Buy
19,567
+5,152
+36% +$532K 0.02% 375
2020
Q1
$1.29M Buy
14,415
+5,716
+66% +$538K 0.02% 432
2019
Q4
$867K Buy
8,699
+177
+2% +$16.7K 0.01% 528
2019
Q3
$760K Sell
8,522
-340
-4% -$29.5K 0.01% 521
2019
Q2
$732K Buy
8,862
+1,456
+20% +$114K 0.01% 603
2019
Q1
$599K Buy
+7,406
New +$584K 0.01% 606
2018
Q3
Sell
-3,548
Closed -$249K 810
2018
Q2
$249K Buy
+3,548
New +$255K 0.01% 683

Other funds holding AZN

Mariner's AZN Position: Q2 2026 in Review

Mariner increased its AstraZeneca (AZN) stake by 3.3% in Q2 2026, buying an estimated $2.33M and bringing the position to 384,328 shares worth $72.9M. The position accounts for 0.08% of the portfolio, ranked #203.

Mariner first reported a position in AZN in Q2 2018 and has held it in 31 quarters since. The position peaked at $73.3M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Mariner held 384,328 shares of AstraZeneca worth $72.9M as of Q2 2026.
  • Mariner bought 12,405 AstraZeneca shares in Q2 2026, an estimated $2.33M.
  • AstraZeneca made up 0.08% of Mariner's portfolio in Q2 2026, its #203 holding.
  • Mariner first reported a position in AstraZeneca in Q2 2018 and has held it in 31 quarters since.
  • Mariner's AstraZeneca position peaked at $73.3M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.